NASD · Healthcare · Biotechnology · USA
Verastem Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Verastem is a biopharmaceutical company developing medicines targeting RAS/MAPK pathway-driven cancers. It markets AVMAPKI FAKZYNJA CO-PACK, a combination therapy for patients with KRAS mutations in recurrent low-grade serous ovarian cancer who have undergone prior treatment. The company's pipeline includes VS-7375, a KRAS G12D inhibitor being evaluated in clinical trials for pancreatic, lung, and colorectal cancers.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Verastem Inc stock.
Overvalued: intrinsic value $3.07 per share, market price $9.34, margin of safety -204.6% (as of 2026-10-20).
A 2.4x revenue multiple, discounted for its losses, values the shares at $3.07; the price of $9.34 is 205% above that value.
Leak Score: 39/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
71 more in this industry show a wider margin of safety.
VSTM is overvalued (as of the 2026-10-20 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $3.07; the price of $9.34 is 205% above that value.
$3.07 per share (as of the 2026-10-20 close), against a market price of $9.34. That is a margin of safety of -204.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
39 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.